What is Brainomix?
Brainomix is an Oxford-based company founded in 2010, emerging from the University of Oxford. It specializes in developing artificial intelligence-driven software designed to enhance the interpretation of medical images, thereby improving patient outcomes for life-saving treatments. The company's flagship e-Stroke platform offers clinicians a comprehensive stroke imaging solution, enabling faster and more informed treatment decisions for patients experiencing suspected strokes. This focus on AI in healthcare positions Brainomix at the forefront of medical technology innovation.
How much funding has Brainomix raised?
Brainomix has raised a total of $52.5M across 5 funding rounds:
Angel/Seed
$1.9M
Series A
$1.6M
Other Financing Round
$9.8M
Series B
$21.2M
Series C
$18M
Angel/Seed (2014): $1.9M with participation from Parkwalk Advisors Limited
Series A (2014): $1.6M led by Chimera Partners and University of Oxford Isis Fund
Other Financing Round (2018): $9.8M supported by Parkwalk Advisors, Oxford University Innovation Fund, Chimera Partners, and Boehringer Ingelheim
Series B (2021): $21.2M featuring Oxford University Innovation Fund, Parkwalk Advisors, Tencent, and Boehringer Ingelheim Venture Fund
Series C (2025): $18M backed by Boehringer Ingelheim Venture Fund, Parkwalk Advisors, and Hostplus
Key Investors in Brainomix
Parkwalk Advisors
Parkwalk Advisors is a prominent venture capital firm specializing in university spinouts and deeptech innovations, particularly those originating from UK institutions. They provide crucial funding and strategic support to early-stage companies, focusing on sectors like AI and HealthTech.
Boehringer Ingelheim
Boehringer Ingelheim is a global pharmaceutical company with a long history, involved in the development of human pharmaceuticals, biopharmaceuticals, and animal health products. Their venture arm often invests in innovative health technologies.
Tencent
Tencent is a major Chinese multinational technology and entertainment conglomerate, known for its significant investments in various technology sectors, including healthcare and AI, through its diverse investment arms.
What's next for Brainomix?
With its recent major strategic investment and a history of substantial capital raises, Brainomix is well-positioned for significant expansion. The company's trajectory suggests a focus on scaling its AI-powered e-Stroke platform globally, further integrating its solutions into clinical workflows, and potentially exploring new applications for its AI technology in other critical care areas. The backing from strategic investors indicates confidence in Brainomix's ability to disrupt the medical imaging market and improve patient care standards worldwide.
See full Brainomix company page
